Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Oxcarbazepine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aucta Announced FDA Approval of A Generic Version of Trileptal®(oxcarbazepine) Oral Suspension
Details : Oxcarbazepine produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. It is indicated to treat parti...
Product Name : Trileptal-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 12, 2022
Lead Product(s) : Oxcarbazepine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxcarbazepine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
USFDA Gives Final Nod to Zydus’ Tablets for Treatment of Seizures
Details : Oxcarbazepine tablets produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. It is indicated to tre...
Product Name : Trileptal-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 07, 2023
Lead Product(s) : Oxcarbazepine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable